Luis De La Cruz Merino

Profesor Asociado CIS
lcruz-ibis@us.es
Área de conocimiento: Medicina
Departamento: Medicina
Grupo: Sin Grupo
Instituto de Inv.: IBIS
Tipo Año Título Fuente
Artículo2021 Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival JOURNAL FOR IMMUNOTHERAPY OF CANCER
Corrección2021 Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer SCIENTIFIC REPORTS
Artículo2021 Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer SCIENTIFIC REPORTS
Artículo2021 Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial JOURNAL FOR IMMUNOTHERAPY OF CANCER
Corrección2021 Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] ANNALS OF ONCOLOGY
Artículo2021 Desarrollo de un protocolo de monitorización de fuga en perfusión de miembro aislado con gammacámara portátil REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
Revisión2021 Immunometabolism modulation in therapy Biomedicines
Artículo2021 Increased blood monocytic myeloid derived suppressor cells but low regulatory T lymphocytes in patients with mild COVID-19 VIRAL IMMUNOLOGY
Revisión2021 Leptin, both bad and good actor in cancer BIOMOLECULES
Artículo2021 Lower survival and increased circulating suppressor cells in patients with relapsed/refractory diffuse large B-cell lymphoma with deficit of vitamin D levels using R-GDP plus lenalidomide (R2-GDP): Results from the R2-GDP-gotel trial CANCERS
Revisión2021 Metabolic classification and intervention opportunities for tumor energy dysfunction Metabolites
Artículo2021 Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) JOURNAL OF CLINICAL ONCOLOGY
Artículo2021 Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival ANNALS OF ONCOLOGY
Artículo2021 SEOM clinical guideline for the management of cutaneous melanoma (2020) CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2020 Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial LANCET ONCOLOGY
Revisión2020 An integral view of cancer (III). Evaluation of new biomarkers and treatment strategies Revista Española de Patología
Resumen congreso2020 Evolution of cytotoxic and regulatory T cells in blood and in tissue after neoadjuvant treatment in breast carcinoma ANNALS OF ONCOLOGY
Artículo2020 GEICAMGuidelines for the Management of Patients with Breast Cancer During theCOVID-19 Pandemic in Spain ONCOLOGIST
Artículo2020 Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice CLINICAL & TRANSLATIONAL ONCOLOGY
Revisión2020 Integrating the tumor microenvironment into cancer therapy CANCERS
Artículo2020 Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report MEDICINE
Artículo2020 Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer NEW ENGLAND JOURNAL OF MEDICINE
Artículo2020 SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019) CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2020 SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer FUTURE ONCOLOGY
Resumen congreso2020 SOLTI-1503 PROMETEO: Combination of talimogene laherparepvec (T-VEC) with atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy CANCER RESEARCH
Revisión2019 2018 Consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary Revista Española de Patología
Revisión2019 An integral view of cancer (I). The study, classification and reprogramming of the tumoral microclimate Revista Española de Patología
Revisión2019 An integral view of cancer (II). Fields of investigation and emerging biomarkers Revista Española de Patología
Resumen congreso2019 Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study CANCER RESEARCH
Artículo2019 Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy TRANSLATIONAL CANCER RESEARCH
Artículo2019 Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q" HEALTH AND QUALITY OF LIFE OUTCOMES
Letter2019 Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group LEUKEMIA & LYMPHOMA
Resumen congreso2019 Evolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy ANNALS OF ONCOLOGY
Resumen congreso2019 Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2019 Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results ANNALS OF ONCOLOGY
Resumen congreso2019 Myeloid derived-suppressor cells in healthy women and in advanced breast cancer patients ANNALS OF ONCOLOGY
Revisión2019 New horizons in breast cancer: the promise of immunotherapy CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2019 Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors JOURNAL FOR IMMUNOTHERAPY OF CANCER
Revisión2019 Obesity and Breast Cancer: Role of Leptin FRONTIERS IN ONCOLOGY
Resumen congreso2019 Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) ANNALS OF ONCOLOGY
Editorial2019 Pneumonitis Related to Melanoma Immunotherapy CLINICAL NUCLEAR MEDICINE
Artículo2019 Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma ONCOLOGIST
Resumen congreso2019 Results from a phase II trial of pembrolizumab (P) plus gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study ANNALS OF ONCOLOGY
Artículo2019 Reunión Anual de la SAPD: Abordaje de la toxicidad hepática tras el tratamiento con inhibidores de checkpoint en vida real Revista Andaluza de Patología Digestiva
Resumen congreso2019 Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population CANCER RESEARCH
Artículo2019 SEOM clinical guidelines in advanced and recurrent breast cancer (2018) CLINICAL & TRANSLATIONAL ONCOLOGY
Revisión2019 The tumour microenvironment as an integrated framework to understand cancer biology CANCER LETTERS
Artículo2019 Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group HEMATOLOGICAL ONCOLOGY
Artículo2019 Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma PLOS ONE
Revisión2018 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary CLINICAL & TRANSLATIONAL ONCOLOGY
Resumen congreso2018 90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial. JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2018 A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative advanced breast cancer: GEICAM/2015-04 PANGEA-Breast CANCER RESEARCH
Artículo2018 Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries EUROPEAN JOURNAL OF CANCER
Resumen congreso2018 Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF(V600) mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study JOURNAL OF CLINICAL ONCOLOGY
Artículo2018 Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma BRITISH JOURNAL OF CANCER
Resumen congreso2018 Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22) JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2018 Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma BLOOD
Artículo2018 MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
Artículo2018 nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial ANNALS OF ONCOLOGY
Resumen congreso2018 Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962) ANNALS OF ONCOLOGY
Artículo2018 Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 JOURNAL OF CLINICAL ONCOLOGY
Artículo2018 Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden JOURNAL FOR IMMUNOTHERAPY OF CANCER
Resumen congreso2018 Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast ANNALS OF ONCOLOGY
Resumen congreso2018 Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study CANCER RESEARCH
Artículo2018 SEOM clinical guideline for the management of malignant melanoma (2017) CLINICAL & TRANSLATIONAL ONCOLOGY
Resumen congreso2017 A phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER+/HER2-advanced or metastatic breast cancer (mBC) that has progressed during or after aromatase inhibitor (AI) therapy JOURNAL OF CLINICAL ONCOLOGY
Revisión2017 Advances in the Immunobiological Therapies for Advanced Melanoma ACTAS DERMO-SIFILIOGRAFICAS
Revisión2017 Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 331
Artículo2017 Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study JOURNAL OF TRANSLATIONAL MEDICINE
Resumen congreso2017 Follicular lymphoma: clinical and mollecular characteristics of histologic transformation ANNALS OF ONCOLOGY
Resumen congreso2017 Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/2 Study Examining G100 Alone and in Combination with Pembrolizumab BLOOD
Resumen congreso2017 Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma JOURNAL OF CLINICAL ONCOLOGY
Artículo2017 More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments EUROPEAN JOURNAL OF CANCER
Resumen congreso2017 Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962. JOURNAL OF CLINICAL ONCOLOGY
Artículo2017 Prognostic Value of Event-Free Survival at 12 and 24 Months and Long-Term Mortality for Non-Hodgkin Follicular Lymphoma Patients: A Study Report From the Spanish Lymphoma Oncology Group CANCER
Artículo2016 Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel BREAST CARE
Artículo2016 Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2016 Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial LANCET ONCOLOGY
Resumen congreso2016 Cost-Utility Analysis of Nivolumab Monotherapy for Metastatic Melanoma Treatment VALUE IN HEALTH
Revisión2016 Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review ENDOCRINE-RELATED CANCER
Resumen congreso2016 Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) plus vemurafenib (VEM) vs placebo (PBO) plus VEM in advanced BRAF-mutated melanoma patients (pts) JOURNAL OF TRANSLATIONAL MEDICINE
Resumen congreso2016 GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases ANNALS OF ONCOLOGY
Letter2016 Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib FARMACIA HOSPITALARIA
Resumen congreso2016 Impact of the addition of rituximab in overall survival in first line chemotherapy in follicular lymphoma: a population-based study from the Spanish Lymphoma Oncology Group (GOTEL) ANNALS OF ONCOLOGY
Resumen congreso2016 Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02 ANNALS OF ONCOLOGY
Artículo2016 Safety of vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: the Spanish experience CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2016 Sam68 Mediates the Activation of Insulin and Leptin Signalling in Breast Cancer Cells PLOS ONE
Resumen congreso2016 Survival in young adults diagnosed with follicular lymphoma in a national registry from the Spanish Lymphoma Oncology Group ANNALS OF ONCOLOGY
Artículo2016 Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study MELANOMA RESEARCH
Resumen congreso2016 Two-year survival and safety update in patients (pts) with treatment-naive advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066 JOURNAL OF TRANSLATIONAL MEDICINE
Artículo2015 Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice CLINICAL & TRANSLATIONAL ONCOLOGY
Resumen congreso2015 Chemotherapy effectiveness in the treatment of non-medullary well-differentiated thyroid cancer: A systematic review JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2015 Follicular lymphoma and clinical characteristics of histologic transformation EUROPEAN JOURNAL OF CANCER
Artículo2015 Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study PLOS ONE
Resumen congreso2015 Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) plus vemurafenib (VEM) in the phase 3 coBRIM study EUROPEAN JOURNAL OF CANCER
Artículo2015 Inmunoterapia en cáncer de pulmón Revisiones en Cáncer
Nota2015 Interview with Dr. L. de la Cruz Merino Revisiones en Cáncer
Resumen congreso2015 Prospective study of the impact of the Prosigna (TM) assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study CANCER RESEARCH
Artículo2015 Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer CURRENT MEDICAL RESEARCH AND OPINION
Resumen congreso2015 Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C) JOURNAL OF CLINICAL ONCOLOGY
Artículo2015 SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2015 SEOM clinical guidelines for the treatment of Hodgkin's lymphoma CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2015 SEOM clinical guidelines in metastatic breast cancer 2015 CLINICAL & TRANSLATIONAL ONCOLOGY
Resumen congreso2015 Survival analysis of follicular lymphoma in a national registry from the spanish oncology lymphoma group EUROPEAN JOURNAL OF CANCER
Resumen congreso2015 Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma JOURNAL OF CLINICAL ONCOLOGY
Artículo2014 Avoidance of Cancer Cell Destruction by the Immune System PATHOBIOLOGY OF HUMAN DISEASE: A DYNAMIC ENCYCLOPEDIA OF DISEASE MECHANISMS
Artículo2014 Clinical guideline SEOM: cancer of unknown primary site CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2014 Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma NEW ENGLAND JOURNAL OF MEDICINE
Resumen congreso2014 Evaluation of changes on tumor-infiltrating lymphocytes and regulatory T-cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast cancer patients and relation with pathologic complete response JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2014 Pathological complete response and changes related to t infiltrating lymphocytes and regulatory t cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast carcinoma ANNALS OF ONCOLOGY
Revisión2014 Radiation for awakening the dormant immune system, a promising challenge to be explored FRONTIERS IN IMMUNOLOGY
Revisión2014 Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma THERAPEUTIC ADVANCES IN HEMATOLOGY
Resumen congreso2013 Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625 JOURNAL OF CLINICAL ONCOLOGY
Revisión2013 New Insights into the Role of the Immune Microenvironment in Breast Carcinoma CLINICAL & DEVELOPMENTAL IMMUNOLOGY
Resumen congreso2013 Pathologic complete response and changes related to T-infiltrating lymphocytes and regulatory T cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast carcinoma JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2013 Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC) JOURNAL OF CLINICAL ONCOLOGY
Artículo2013 The prevalence and nature of cancer-related neuropathic pain in out-patient services in Spain Open Pain Journal
Resumen congreso2012 Consolidaton treatment with Y90-ibritumomab tiuxetan after r-chop induction in high-risk patients with follicular lymphoma (fl) ( gotel -fl1lc): A multicentric, prospective study ANNALS OF ONCOLOGY
Revisión2012 Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications CLINICAL & DEVELOPMENTAL IMMUNOLOGY
Revisión2011 Immune Microenvironment in Colorectal Cancer: A New Hallmark to Change Old Paradigms CLINICAL & DEVELOPMENTAL IMMUNOLOGY
Letter2011 Numb chin syndrome: A warning sign of aggressive B-cell malignancy LEUKEMIA RESEARCH
Artículo2010 Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety ONCOLOGIST
Artículo2010 Linfangitis carcinomatosa como presentación de un adenocarcinoma gástrico Revista Andaluza de Patología Digestiva
Artículo2010 Primary intracranial malignant peripheral nerve sheath tumour responding to chemotherapy CLINICAL & TRANSLATIONAL ONCOLOGY
Revisión2010 Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
Artículo2009 Linfocitos infiltrantes de tumor. Implicación en el cáncer colorrectal Revista Andaluza de Patología Digestiva
Artículo2009 Role of transforming growth factor B in cancer microenvironment CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2009 Role of transforming growth factor beta in cancer microenvironment CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2008 Cancer and Immune Response: Old and New Evidence for Future Challenges ONCOLOGIST
Artículo2008 Obstrucción intestinal maligna, sintomatología depresiva y solicitud de «eutanasia» Medicina Paliativa
Resumen congreso2008 Phase II: Sequential scheme capecitabine-oxaliplatin followed by capecitabine-irinotecan ( oxxec-02) in first line metastatic colorectal cancer (mcrc). Study oxxec-02 ANNALS OF ONCOLOGY
Letter2007 Severe acute hepatitis in a patient treated with anastrozole LANCET
Artículo2005 Cáncer de páncreas. Epidemiología, historia natual y estadificación Revisiones en Cáncer
Artículo2005 Cáncer de vejiga: historia natural Revisiones en Cáncer
Revisión2005 Pancreatic cancer. Epidemiology, natural history and staging Revisiones en Cáncer
Resumen congreso2004 A multicenter sequential phase IV study of oxaliplatin (Oxa) and capecitabine (Cap) followed by irinotecan (Iri) and capecitabine in first line advanced colorectal cancer (ACC). Preliminary results JOURNAL OF CLINICAL ONCOLOGY
Editorial2004 Beneficio clínico: beneficio ¿para quien? Oncología
Artículo2003 Historial natural y estadificación del cáncer de cabeza y cuello Revisiones en Cáncer
Revisión2003 Natural history and staging of head and neck cancer Revisiones en Cáncer
El investigador no tiene ningún proyecto asociado